China Plans Clinical Data Protection By Product Category For First Time

Up To Six Years For Novel Small Molecules, Biologics

After almost seven years, China’s NMPA has once again published draft measures for clinical trial data protection, opening these up to public comments. While specific protection periods by drug category are proposed, some clarifications are still needed.

Regulation updates
(Shutterstock)
Xu Hu

Read more by Xu Hu

Xu is a senior reporter and covers aspects on policy and regulations in China pharma industry within the APAC Pharma news team.

More from China

More from Pink Sheet